BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33858047)

  • 1. [The prognostic impact of diabetic mellitus and hyperglycemia during DLBCL treatment on patients with diffuse large B-cell lymphoma].
    Hu Y; Xu YJ; Li MZ; Lan YX; Mao L; Ning QY; Xu W; Yang HL; Zhang YZ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):151-157. PubMed ID: 33858047
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 3. Diminishing prognostic role of preexisting diabetes mellitus for patients with diffuse large B-cell lymphoma in the rituximab era.
    Lu HJ; Huang YC; Liu CY; Hung MH; Hu MH; Wu CY; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1495-501. PubMed ID: 23712292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
    Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
    Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
    Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparison of Different Staging Systems and Prognostic Analysis in 68 Cases of Primary Intestinal Diffuse Large B Cell Lymphoma].
    Wang X; Wang CY; Xu W; Yang HL; Zhao HF; Wang XF; Wang YF; Yu Y; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):52-60. PubMed ID: 30738447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic Value of Pre-treatment Albumin/Fibrinogen Ratio in Patients with Diffuse Large B-cell Lymphoma].
    Deng H; Zhang L; Wang HY; Huang MJ; Wei J; Zou XL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):762-768. PubMed ID: 37356937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
    Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
    Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
    Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic Value of Anemia and C-Reactive Protein Levels in Diffuse Large B-Cell Lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):671-9. PubMed ID: 26361646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma.
    Pan BH; Kong YL; Wang L; Zhu HY; Li XT; Liang JH; Xia Y; Wu JZ; Fan L; Li JY; Xu W
    Leuk Lymphoma; 2021 Feb; 62(2):291-299. PubMed ID: 33063579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma.
    Zhou W; Li W; He C; Ma R; Gao Q; Wang Y; Feng L; Liu L
    Diabetes Metab Syndr Obes; 2022; 15():2039-2049. PubMed ID: 35860311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establishment and Clinical Significance of Prognostic Nomogram Model for Diffuse Large B-Cell Lymphoma Based on Immunohistochemistry Markers and International Prognostic Index Scores].
    Xu YW; Zhou YL; Kong FC; Chen ZW; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):753-761. PubMed ID: 37356936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
    Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.